Outcomes with Ibrutinib by Line of Therapy in Patients with CLL: Analyses from Phase 3 Data
Ibrutinib, a first-in-class, once-daily inhibitor of Bruton's tyrosine kinase, is indicated by the US FDA for the treatment of patients with CLL/small lymphocytic lymphoma, and allows for treatment without chemotherapy.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Nishitha Reddy, Susan O'Brien, John Byrd, Peter Hillmen, Steven Coutre, Jennifer Brown, Paul Barr, Jacqueline Barrientos, Stephen Devereux, Tadeusz Robak, Thomas Kipps, Alessandra Tedeschi, Florence Cymbalista, Paolo Ghia, Stephen Chang, Joi Ninomoto, Dan Source Type: research